Current Environment:

Summary

This research study is evaluating bone mineral density in childhood cancer survivors who have a history of bone fracture.

Conditions

Bone Mineral Density, Childhood Cancer Survivors

Recruitment Status

Recruiting

Detailed Description

The purpose of this research study is to learn more about the status of bones in children and young-adults who have had bone fractures after treatment for childhood cancer. Bone complications including fracture can be important issues for some childhood cancer survivors. In this study we are measuring bone mineral density in children and young adults who have had bone fracture after treatment for childhood cancer. We will measure bone mineral density in two ways. We will use: 1) dual energy x-ray absorptiometry (also known as DXA), and 2) peripheral quantitative computed tomography (also known as pQCT).

Eligibility Criteria

Inclusion Criteria:

History of childhood cancer
Age ≥ 8 years and < 20 years at time of enrollment
≥ 2 years since completion of cancer-directed therapy for first cancer
Received chemotherapy for treatment of childhood cancer
History of bone fracture after the conclusion of chemotherapy*
Not currently receiving cancer-directed therapy
Signed written informed consent (by parent if patient is < 18 years of age, or by patient, if he or she is ≥18 years of age)
Patient assent for those ≥10 years of age and < 18 years of age for whom a parent provides informed consent (*History of bone fracture will be based on patient/parent report of fracture occurrence and will be confirmed in review of the medical record whenever feasible.)

Exclusion Criteria:

Current treatment with bisphosphonates (as of time of enrollment)
Current treatment with the anticonvulsant depakote (at time of enrollment)
Currently pregnant

Intervention

Intervention Type

Intervention Name

Other

Dual energy x-ray absorptiometry (DXA)

Other

Peripheral quantitative computed tomography (pQCT)

Gender

All

Min Age

8 Years

Max Age

20 Years

Download Date

September 9, 2021

Principal Investigator

Lynda Vrooman

Primary Contact Information

Lynda Vrooman, MD

(617) 632-2659

lynda_vrooman@dfci.harvard.edu

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team: